All Posts

Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma

There’s good news on the treatment horizon for two typically slow-growing versions of lymphoma: follicular lymphoma and marginal zone lymphoma. Research presented by physicians from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, at the American Society of Hematology’s 2024 meeting in San Diego describes positive results for the antibody drug loncastuximab tesirine (Zynlonta) in patients with high-risk forms of these two blood cancers.

Restoring HOPE: UF Health’s Oncofertility Program

Cancer is never part of the plan, nor is giving up the dream of having children. UF Health’s Oncofertility Program empowers patients with cancer to take control of their future by preserving their fertility.

Building a heart-healthy future: Cardio-Oncology Symposium cultivates innovative research

By bringing together clinicians, patient advocates and researchers across disciplines, the UF Cardio-Oncology Symposium on April 3 provided an engaging forum to spark new research collaborations. The event showcased how innovations in precision medicine, early detection and multidisciplinary collaboration are directly enhancing patient care, ensuring the cancer patient of today does not become the cardiac patient of tomorrow.

Viral Mimicry May Enhance Immune Response Against Glioblastomas

New research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, scientists has found that targeting ZNF638, a “master regulator” protein that silences retroviruses, can induce an antiviral response in glioblastoma.

Moffitt Working To Improve Access to Care for Rural Patients

When he retired to Sebring from Atlanta in 2014, Dennis Davis had a plan: fish and spend time with his wife, Deb. Despite ongoing treatment for prostate cancer and tongue cancer, the 75-year-old said he has been able to do that thanks to the ongoing care he’s received at Moffitt Cancer Center. It’s a two-plus hour drive to Tampa for his appointments, but he’s more than happy to make the trek, he said.

Sylvester Researchers Study Quality of Life During Immunotherapy Treatment

Immune checkpoint inhibitors have been a game-changer in oncology. Tumors often have proteins on them that tell your immune system not to attack. Checkpoint inhibitors — which work by blocking these proteins so your immune system continues to fight the tumor — have provided new options for many people with advanced or metastatic cancer who were left with limited options.

UF biostatistician at the forefront of groundbreaking childhood leukemia drug trial

Adding one drug to a chemotherapy regimen for children with acute lymphoblastic leukemia decreased risk of relapse by about two-thirds, according to a study designed in part by John Kairalla, Ph.D., the senior statistician on the clinical trial and research associate professor and associate program director of the Children’s Oncology Group Statistics and Data Center in the College of Public Health and Health Professions’ Department of Biostatistics.

Sylvester Logo